Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032245899> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W3032245899 endingPage "238" @default.
- W3032245899 startingPage "235" @default.
- W3032245899 abstract "Objective To evaluate the effectiveness and safety of terazosin in the treatment of benign prostatic hyperplasia (BPH)patients with concomitant hypertension.Methods A singlecenter prospective clinical observational study was conducted from March,2006 to March,2010 in our center.The main endpoints were the changes of IPSS total score,diastolic and systolic blood pressures at the end of 4 weeks and 3 monthes compared with the baseline,The second endpoints were Qmax value at the end of 4 weeks and 3 monthes compared with the baseline,Safety was assessed by adverse events.Results There were 212 patients in the study recruited,and 189 patients completed the study.All patients had BPH combined with hepertension.All patients were randomly devided into two statistical analysis group,blood pressure well controled and not well controled group,In the well controlled group,the IPSS socre reduced from 22.31 ± 5.18 at baseline to 15.64 ±3.91 at the end of the 4th weeks and 13.16 ± 3.53 at the end of 3rd monthes in the blood pressure well controled group populatin( P ＜ 0.01 ).The Qmax were improved significantly from (7.87 ± 2.41 ) ％ at baseline to (14.19 ±2.64)％ at the end of the 4th weeks and (15.69 ±2.77)％ at the end of3rd monthes in the blood pressure well controled group populatin( P ＜ 0.01 ).Terazosin had moderate effect in blood pressure decreasing (P ＜ 0.05 ),and all patients were within normal blood pressure range.In the uncontrolled group,the IPSS socre reduced from 21.55 ± 4.82 at baseline to 15.44 ± 3.66 at the end of the 4th weeks and 12.96 ± 3.11 at the end of 3rd monthes in the blood pressure well controled group populatin (P ＜ 0.01 ).The Qmax were improved significantly from ( 8.27 ± 2.27 ) ％ at baseline to ( 14.26 ± 2.87) ％ at the end of the 4th weeks and ( 15.51 ±2.92) ％ at the end of 3rd monthes in the blood pressure well controled group populatin( P ＜ 0.01 ).Terazosin decreased BPH patient blood pressure with controlled patients and unctrolled patients additionaly to other blood pressure medicine (P ＜ 0.05 ),and no severe side effect occured.At the end of the study,all patients were taking drug continuously and were followed.Conclnsion Terazosin can significantly improve the symptoms and quality of life in BPH patients with hypertension with good safety and compliance.Key words: Terazosin; Benign prostatic hyperplasia; Hypertension" @default.
- W3032245899 created "2020-06-05" @default.
- W3032245899 creator A5016397082 @default.
- W3032245899 creator A5016980869 @default.
- W3032245899 creator A5042792723 @default.
- W3032245899 creator A5050654097 @default.
- W3032245899 date "2012-03-01" @default.
- W3032245899 modified "2023-09-24" @default.
- W3032245899 title "Clinical study on the effectiveness and safety of terazosin in the treatment of benign prostatic hyperplasia patients with concomitant hypertension" @default.
- W3032245899 doi "https://doi.org/10.3760/cma.j.issn.1008-6315.2012.03.004" @default.
- W3032245899 hasPublicationYear "2012" @default.
- W3032245899 type Work @default.
- W3032245899 sameAs 3032245899 @default.
- W3032245899 citedByCount "0" @default.
- W3032245899 crossrefType "journal-article" @default.
- W3032245899 hasAuthorship W3032245899A5016397082 @default.
- W3032245899 hasAuthorship W3032245899A5016980869 @default.
- W3032245899 hasAuthorship W3032245899A5042792723 @default.
- W3032245899 hasAuthorship W3032245899A5050654097 @default.
- W3032245899 hasConcept C126322002 @default.
- W3032245899 hasConcept C126894567 @default.
- W3032245899 hasConcept C188816634 @default.
- W3032245899 hasConcept C197934379 @default.
- W3032245899 hasConcept C2776679619 @default.
- W3032245899 hasConcept C2777562237 @default.
- W3032245899 hasConcept C2779384505 @default.
- W3032245899 hasConcept C71924100 @default.
- W3032245899 hasConcept C84393581 @default.
- W3032245899 hasConceptScore W3032245899C126322002 @default.
- W3032245899 hasConceptScore W3032245899C126894567 @default.
- W3032245899 hasConceptScore W3032245899C188816634 @default.
- W3032245899 hasConceptScore W3032245899C197934379 @default.
- W3032245899 hasConceptScore W3032245899C2776679619 @default.
- W3032245899 hasConceptScore W3032245899C2777562237 @default.
- W3032245899 hasConceptScore W3032245899C2779384505 @default.
- W3032245899 hasConceptScore W3032245899C71924100 @default.
- W3032245899 hasConceptScore W3032245899C84393581 @default.
- W3032245899 hasIssue "03" @default.
- W3032245899 hasLocation W30322458991 @default.
- W3032245899 hasOpenAccess W3032245899 @default.
- W3032245899 hasPrimaryLocation W30322458991 @default.
- W3032245899 hasRelatedWork W145491073 @default.
- W3032245899 hasRelatedWork W1979068176 @default.
- W3032245899 hasRelatedWork W1990854157 @default.
- W3032245899 hasRelatedWork W2032580900 @default.
- W3032245899 hasRelatedWork W2058207372 @default.
- W3032245899 hasRelatedWork W2092999665 @default.
- W3032245899 hasRelatedWork W2352358224 @default.
- W3032245899 hasRelatedWork W2366089435 @default.
- W3032245899 hasRelatedWork W2374749822 @default.
- W3032245899 hasRelatedWork W2376502893 @default.
- W3032245899 hasRelatedWork W2381765069 @default.
- W3032245899 hasRelatedWork W2391472144 @default.
- W3032245899 hasRelatedWork W2392987912 @default.
- W3032245899 hasRelatedWork W2398474405 @default.
- W3032245899 hasRelatedWork W2405774089 @default.
- W3032245899 hasRelatedWork W2418639435 @default.
- W3032245899 hasRelatedWork W2443975153 @default.
- W3032245899 hasRelatedWork W3030760260 @default.
- W3032245899 hasRelatedWork W3032553987 @default.
- W3032245899 hasRelatedWork W3012065715 @default.
- W3032245899 hasVolume "28" @default.
- W3032245899 isParatext "false" @default.
- W3032245899 isRetracted "false" @default.
- W3032245899 magId "3032245899" @default.
- W3032245899 workType "article" @default.